RO5093151 clinical trials
Also written RO5093151.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses RO5093151 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RO5093151
- 4
Studies by the year they started
4 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Atazanavir (1) · Ritonavir (1) · RO-5027838 (1)
Studies
Open first, then newest update. How each study uses RO5093151 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedPhase 1Hoffmann-La RocheNCT01277094Written as RO5093151
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01591850Written as RO5093151
- A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle GlaucomaCompletedPhase 2Hoffmann-La RocheNCT01493271Written as RO5093151
- A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of MetforminCompletedPhase 2Hoffmann-La RocheNCT00823680Written as RO5093151